The Asia Pacific radiation oncology market size is expected to reach USD 4.02 billion in 2030 and is projected to grow at a CAGR of 11.6% from 2025 to 2030. Technological advancements in radiation therapy over the years is one of the key factors responsible for market growth.
Advancements in computers have resulted in faster, smarter, and more capable treatment planning and have enabled constant imaging guidance, more precise dosing, and delivery of higher doses. This has resulted in greater efficiency and lesser adverse effects. For instance, in April 2018, Manipal Hospitals in India introduced brachytherapy facilities for the treatment of gynecologic cancers, including endometrial and cervical cancers. In addition, major key players are increasingly focusing on the development and launch of new and innovative brachytherapy products.
Furthermore, rising strategic initiatives by hospitals and key players to adopt new technologies are expected to boost market growth. For instance, in May 2019, Accuray, Inc. entered into an agreement with Hong Kong Sanatorium and Hospital (HKSH) for the acquisition of two Synchrony motion tracking and correction technology to be used with Radixact Systems.
In addition, increasing approval by regulatory bodies to enhance access to advanced radiation therapy for patients and clinicians is anticipated to drive the market. For instance, in March 2020, Varian received approval from the China National Medical Products Administration (NMPA) for the Halcyon 2.0 treatment system.
The rising installation of new radiotherapy systems in hospitals by manufacturers is anticipated to accelerate market growth. For instance, in June 2019, Varian installed the ProBeam Compact single-room proton therapy system for Cyclotron at King Chulalongkorn Memorial Hospital in Thailand.
An increasing number of proton centers to combat the rising demand for accurate and effective radiation therapy technologies is anticipated to boost the market over the forecast period. For instance, in January 2019, IBA opened Apollo Proton Cancer Centre in India to treat patients with proton therapy systems such as Proteus PLUS.
Elekta AB and Accuray Incorporated are expected to hold a majority of share in the market over the forecast period. Elekta AB is geographically expanding in markets outside China and an increasing number of installed units are expected to reach the end of the life cycle, further requiring replacements, service, and support. Furthermore, Accuray Incorporated is focusing on strategic collaborations to attain a high market share. For instance, in January 2019, Accuray Asia collaborated with China Isotope and Radiation Corporation’s wholly-owned subsidiary, CNNC High Energy Equipment (Tianjin) Co., Ltd. to develop and sell radiation oncology systems in China.
Request a free sample copy or view report summary: Asia Pacific Radiation Oncology Market Report
External beam radiation therapy (EBRT) dominated the market with a revenue share of 35.9% in 2024.
Internal beam radiation therapy is expected to grow at the fastest CAGR of 16.5% over the forecast period.
Applications in breast cancer under the EBRT segment led the market with 26.3% of the total revenue share in 2024, driven by EBRT’s effectiveness, increased awareness, and early detection initiatives.
Grand View Research has segmented the Asia Pacific radiation oncology market report based on type, technology, application, and country
Asia Pacific Radiation Oncology Type Outlook (Revenue, USD Million, 2018 - 2030)
External Beam Radiation Therapy
Electron-emitting high-energy Linear Accelerators (Linac)
MRI LINACs
Compact Advanced Radiotherapy Systems
Cyberknife
Gamma Knife
Tomotherapy
Proton Therapy
Segment
Cyclotron
Synchrotron
Internal Beam Radiation Therapy
Brachytherapy
Seeds
Applicators and Afterloaders
Electronic Brachytherapy
Systemic Beam Radiation Therapy
Others
Asia Pacific Radiation Oncology Technology Outlook (Revenue, USD Million, 2018 - 2030)
External Beam Radiation Therapy
Image-Guided Radiotherapy (IGRT)
Intensity Modulated Radiotherapy (IMRT)
Stereotactic Technology
Proton Beam Therapy
3D Conformal Radiotherapy (3D CRT)
Volumetric Modulated Arc Therapy (VMAT)
Brachytherapy
HDR Brachytherapy
LDR Brachytherapy
Asia Pacific Radiation Oncology Application Outlook (Revenue, USD Million, 2018 - 2030)
External Beam Radiation Therapy
Prostate Cancer
Breast Cancer
Lung Cancer
Head and Neck Cancer
Colorectal Cancer
Others
Internal Beam Radiation Therapy
Prostate Cancer
Gynecological Cancer
Breast Cancer
Cervical Cancer
Penile Cancer
Others
Asia Pacific Radiation Oncology Country Outlook (Revenue, USD Million, 2018 - 2030)
Japan
China
India
South Korea
Australia
Singapore
New Zealand
Malaysia
Thailand
Indonesia
Vietnam
List of Key Players in Asia Pacific Radiation Oncology Market
NTP Radioisotopes SOC Ltd
Varian Medical Systems, Inc.
Nordion Inc.
Mevion Medical Systems
Perspecitve Therapeutics Inc.
Accuray Incorporated
BD
IBA Radiopharma Solutions
Elekta
Curium
"The quality of research they have done for us has been excellent..."